Venus Medtech (hangzhou), Inc. Class H · HKEX:2500
Venus Medtech (hangzhou), Inc. Class H — H1 2026 Earnings Presentation
28 slides from Venus Medtech (hangzhou), Inc. Class H's earnings presentation, Oct 8, 2026
Slide 1: Venusmedtech (2500.HK) 2026 Interim Results and Business Update
@ SORE VENUSMEDTECH FAR ERTF (2500.HK) 4 20265 Pikes Ba Venusmedtech (2500.HkK) 2026 Interim Results and Business Update
Slide 2: $F FS AA a0
$F FS AA a0 \VENUSMEDTECH BISMBADRRRTHSH, RETHRRTMH, ATR PIRMAR: RATHER N SET ERR AA RAS) (FM AAS) “) ERASSHCWATMES, SHRKES. ARATMAEABATM MRAM RiGCAR ENS HNS E. EAAMANAMEM SNES SME AAI. HEME. TEER ERE MN EAATRERTARARRIE, ETAT MARMASSE AER. ACADMAE PER. ER, BAR. AthA. RA. ARAL, CAL ARAK, WAMABRARATRE
Slide 3: Agenda
fabAefy VENUSMEDTECH iS 2026 ovr mee mlkete Bi Se IRAN TEAL BS Was ANGER AMSA pace 03
Slide 4: Section 01
071 1A ARE ENTE IS AM
Slide 5: Company overview and key facts
51270 “AR+a” FRARARTR: GRAB, DRE feBAbeiy VENUSMEDTECH RADE R REE YBBR SL = Maem (ARAe) REBAR 43.3% AeRREONERE A té *i zm 5 EE: FARE (SRLIUZ / MA HL.IZ) , = Zr ARM HQOTILT + FBR, MRE DENT KREASARGRES si (421829%) 1.85{Zi8 IEG 31.5% fife eeastat won 1070 a BL ISRBRAR, BRIE, MEER ORE A ” < 3.801285 LS
Slide 6: VENUSMEDTECH
VENUSMEDTECH
Slide 7: 2026 H1 business highlights
2026 ES WAAR - SIA GRERHERRAR FR ° 51 AFAR AR AR TAA SRNBMRAS HT URAR RBS, WAAR AA TR IASIZ TCA RR Th AY BB HRS + IR30A RASH ITRAR, 5) Kk FRIAR ER AR 2 UR 2 A a PEE = RMR HR GaCardiovalve Target ERB8CE MDR EM RIAL, PT2027E EPR + RESP ower-X PERERA ALS ALR, SSMS, Mit PwAEARH, (Bl254230-F EINMPAMIEREA
Slide 8: Cardiovalve patent litigation timeline
Cardiovalvei ¢ 2027.04 SEMEN RASH REA @: 5212287 LED Edwards Lifesciences Corp.& SD ws Lifesciences LLC SGA \VENUSMEDTECH 2028.11.13 sem - CLOSED 2026-01 — 2026-06 JFSMER - Pleading Stage UR. BA, SHSRI OR; ARS SPOOR Abe Seam 2026-01 2026-03 2026-04 2026-06 RRMA, WER REM EG MRE AE RIAL (Motion to Dis
Slide 9: Pi-Cardia ShortCut cooperation
\VENUSMEDTECH EL Pi-Cardia RAT 8,000 HITCH RA aORESy aay... . aH wy Pi-Cardia sortie 2020% FAST . FDA Ht BRASH besvivant FATT ENR A Ea d .. FHP TAVR $e iA UE MER ch RKIAS IBGE RMR We BA RA RS + BY + WSs RAT HA aes | PRAHA LES WL LRP ER, RITZRAAME DEBE, BAHAR BREE, RN. GARE RAT BRA BOR ShortCut™ 438t
Slide 10: FRE BN 23) ALES - BCA FUL 2) J leg
FRE BN 23) ALES - BCA FUL 2) J leg + Ser ahIRr ak Sr aphresen te + 3) \mE aR x + SHOR Rae PEAT AHH + RATT ASHI + Cardiovalve=RiR B38 BRAT AKG! + TH ESh linda te FRASER Pr para / Sa eee + FP REBIE | RS ARE + BREWS eH i APR B ARROWS
Slide 11: ib ane ee
03 ib ane ee FO lita ARE
Slide 12: Product portfolio
Pane @ ies ea \VENUSMEDTECH VenusA-Valve BTHE, GA. APM, RESIST VenusA-Plus BFE. ARMA. CMSRS4 THR VenusA-Pro BFE, BR. @Ph. RESITHRR Eh BIR(TAVR) = VenusA-Deluxe BFPast Venus-Powerx | BERPB RAM RARS A PRE, 2H), SPURTE Venus-Vitae SEM RAT A PRE. SF, BARE RI VenusP-Valve BF. tt. TEA, HSE. PRSOOZ TRIG; Z
Slide 13: Product pipeline and milestones
Be RAZ CFG cae Eells PR Be PL AC =RMRE= SHIR PRmit | 20284 FEATS Ba Cardiovalve + SRM B RET CER RTE hm PRTC 5c AR 1506 AR AB, HOBRCEEMA Vio CEEMRIFH, Mit MER FRINER 2027S EACERH © SRAM ER HR HE Ul RS Fras SRF BMI 2027H1 DRA Aion RF eR ‘i J Venus-PowerX Venus-Vitae VenusP-Valve See Sure * 202244 A BR
Slide 14: VenusP-Valve long-term follow-up data
VenusP-Valve: 1LOSFREI;iERAM mA KS AE enn PET HRA LOS RHC, 1-104 AERC BS KAIRIE AR TE RSE SAS, Aa 1-10 HaHa m Kh BACAR AEMMETERUEL SEBS 10 5 3.64% 3.64% 3.64% a s 6 hOU 0 « ABA an SY 10Y ML eo RULE iE: RGAE F2026F5A RAIMA FAM (OCC 2026) IEMA Rat pe RRS a 10% 100% 80% 60% 40% 20% 0% 0% BY 52.00% 44.0
Slide 15: Cardiovalve clinical data
Cardiovalve= 2: SiRF nis 3 si (SORT \VENUSMEDTECH ASR Tile RAE RIGO; KCCQ, EMWTEIAS REXNS, SHPARSSHEA tt 2 Hi eLBRF (TR Severity) 12T AKCCQPRBIE RITE 127 A6MWTPRS te TL *No Severe TR OVER 30 days 1000 90 400 re 3995 36% son 80 350 soo 392% 7 9 300 : >10% Massive) 60 om Torrentat 250 ; ate 50 s 200 0
Slide 16: Cardiovalve 30-day safety outcomes
\VENUSMEDTECH Cardiovalve= 2: SiRF nis 3 si (SORT Afa30 RA RSCREZH ARSE, SAREE, KAR eR EH 30-Day MAEs Ries; ue — WS Enhanced All cause Mortality 9/157 (5.7%) 5/57 (8.8%) 4/100 (4%) Heart Failure re-hospitalization 4/157 (2.5%) 1/57 (1.8%) 3/100 (3%) Reintervention 6/157 (3.8%) 1/57 (1.8%) 5/100 (5%)
Slide 17: Cardiovalve clinical data
Ca rdiovalve=34 Sih mar Mee @ snes fe) Cardiovalvela, AbAa RH Hae Nabe sty 35 70.0 60.0 30.0 60.0 50.0 25.0 50.0 40.0 20.0 40.0 30.0 15.0 30.0 20.0 10.0 20.0 5.0 10.0 10.0 00 00 0.0 Baseline 30days_ © 6 Months _12Months Baseline 30days © 6 Months —_12Months Baseline 30days 6 Months —_12Months EEF 20
Slide 18: —WEZRRAOER, HRARLS TAR emer
—WEZRRAOER, HRARLS TAR emer WE2026F8AA, GIRUHAIMACRNRERSPNS, BPH. SE. WN, BN. VRSHR, ABsnnHRWLAl SAME Ht SRW (HIS) RURSA) (IB) Shit (EH) iil 115% 7945 355 PCT HB PHS HBS SA pace 18
Slide 19: VENUSMEDTECH
[=] VENUSMEDTECH
Slide 20: 2026 H1 operating highlights
\VENUSMEDTECH 202657 FF BAIMLS SHE a el eae BALSSBABY Fike aeysy THAR AE AB 17002 T70x 1534 SEAR ESMk eS OLE Bais SEEMS ae ~ ane 104 semis 530 a 350 RR HEWN, shaR. dbSe. HSE pace 20
Slide 21: 2026 H1 revenue by product
MEDTECH 20267 EFFWARM eenery 20255F1H oa j= 2.99% aa 1.38{Z7t Ung 74.0% Xx BR A BTAVR BTPVR BERIT an coe | 6s . a me 14627 si . 0.851278 =— 78.2% A 0.411270 Xx mA EDN pace 21
Slide 22: MWB ERR, BINLS NOL eo,
MWB ERR, BINLS NOL eo, WBINKA SLE Thea LL Es) “St: AREA She CAA) 20254F1H 16.0 : 140 >) 128 (cay 2% ies 10.0 8.0 20264F1H 60 37.4% 4o 20 0.0 2025H1 2026H2 FILES I< PAGE 22
Slide 23: Cost and expense results
SB See — HS KER. FRADE. TGA faba fr “S40: ARMED “Sl: ARMAA “Sl: ARMEAR 140.0 80.0 et eat 120.0 Petes a 5.7% 1005 \20.7% aaa 6.5% ps7 100.0 120.9 60.0 54.8 5u7 ey 120.0 80.0 100.0 40.0 60.0 80.0 60.0 40.0 20.0 40.0 20.0 208 00 00 00 2025 H1 2026H1 2025 H1 2026H1 2025 H1 2026H1 20265 LF iE ABE Leib 49
Slide 24: 2026 H1 EBITDA
20265F FF SFEBITDADin/ [RAR lleaeg VENUSMEDTECH EBITDASti RAIS “Sl: AREA “el: ARBEAT 160.0 SPER SRS HEMIEBITDA 250.0 141.0 140.0 194.6 200.0 120.0 100.0 138.6 82.0 150.0 80.0 60.0 100.0 40.0 50.0 20.0 0.0 0.0 2025 H1 2026H1 2025H1 2026H1 SiR MNESRALLARERAT 20265 HSI RRM RAR L ie, BASSET ao mee Pa BM
Slide 25: Upcoming milestones
202 0262 BIN ith TEFL eh Ee FEROS + Picardiakk TERME + BBEP RM Ka #1 RIPE + DBORARELPHRSIRMMNA + CardiovalvehVAtrAtRmARH Meh + RARACH 20264 AIS] ABR AERA ° HDPE TT AS A PAGE 25
Slide 26: 05 Appendix
Slide 27: 2026 H1 financial statements
2026 FF FN ART Ala else \VENUSMEDTECH Pile Bra Fr AR 2026H1 2025H1 FES 2025/12/31 Wr 135,498 187,137 27.6% bia an Yk, FBBGRE 65,599 72,559 alo (41,977) (49,149) -14.6% eR 21,785, 43,677 LLL te) Be =A 93,521 137,988 -32.2% ae SEH UES i sical sal cas RUA 363,792 393,825 SOA RRO AH BB 128,626 171,051 I
Slide 28: Thank you
VENUSMEDTECH THANK YOU aa
Venus Medtech (Hangzhou) — H1 2026 Earnings Presentation on 6ix